Loading…
Lantern Pharma Inc. is projected to rise to $5.46 by 2027, a +65% move from its current price of $3.31. LTRN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.12 | $3.31 | $3.51 | 0.00% |
| May 30 | $3.05 | $3.31 | $3.59 | -0.01% |
| May 31 | $2.99 | $3.31 | $3.66 | -0.01% |
| Jun 1 | $2.95 | $3.31 | $3.72 | -0.01% |
| Jun 2 | $2.91 | $3.31 | $3.77 | -0.02% |
| Jun 3 | $2.87 | $3.31 | $3.81 | -0.02% |
| Jun 4 | $2.84 | $3.31 | $3.86 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.84 | $3.31 | $3.86 | -0.02% |
| Week 2 | $2.66 | $3.31 | $4.11 | -0.04% |
| Week 3 | $2.54 | $3.31 | $4.31 | -0.06% |
| Week 4 | $2.43 | $3.31 | $4.49 | -0.09% |
| Week 5 | $2.35 | $3.31 | $4.66 | -0.11% |
| Week 6 | $2.27 | $3.31 | $4.81 | -0.13% |
| Week 7 | $2.20 | $3.31 | $4.96 | -0.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lantern Pharma Inc. is a healthcare company focused on the discovery and development of oncology drugs, with operations described as being in India. Its product pipeline includes LP-300 in phase 2 (in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma), LP-184 in phase 1a (for advanced or metastatic solid tumors, unresectable or recurrent GBM and other CNS cancers, plus other solid tumors such as pancreatic, breast, bladder and lung cancers), LP-284 in phase 1 (for non-Hodgkin’s lymphomas including mantle cell lymphoma and double hit lymphoma), STAR-001 in preclinical development for glioblastoma and related CNS cancers, and an antibody drug conjugate program.
The company also runs AI-driven collaborations and multiple partnerships, including with Oregon Therapeutics to optimize XCE853, TTC Oncology for TTC-352 in metastatic ER+ breast cancer, and Actuate Therapeutics for cancer and inflammatory disease indications leading to fibrosis. Lantern Pharma was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc. trades under the ticker LTRN in the healthcare space and currently lists a price of $3.50 with a market capitalization of $44.66M, and a rank of 4643. The stock sits within a broad, ongoing forecast that envisions meaningful long-term upside while showing near-term volatility.
A major floor 66.2% below — a decisive break under it would weaken the trend.
The nearest floor, 40.2% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 34.4% above — clearing it would confirm fresh momentum.
Key LTRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LTRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.34 | Sell | $3.29 | Buy |
| MA 10 | $3.16 | Buy | $3.11 | Buy |
| MA 20 | $2.63 | Buy | $2.83 | Buy |
| MA 50 | $2.31 | Buy | $2.59 | Buy |
| MA 100 | $2.65 | Buy | $2.71 | Buy |
| MA 200 | $3.28 | Buy | $3.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.53 | Neutral |
| Stoch RSI (14) | 76.38 | Neutral |
| CCI (20) | 84.35 | Neutral |
| Williams %R (14) | -13.01 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 57.62 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 86.99 | Sell |
| TRIX (15) | 1.32 | Buy |
| Awesome (5,34) | 0.81 | Buy |
| Ultimate (7,14,28) | 65.20 | Neutral |
| Momentum (10) | 1.25 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 3.48 | Sell |
| ADX (14) | 25.87 | Buy |
| ATR (14) | 0.14 | Info |
Technical sentiment is bullish, with RSI(14) at 70. The 50-day simple moving average sits at $2.28 and the 200-day simple moving average at $3.30, framing a near-term mix of support and resistance. Immediate support is identified at $1.98 and immediate resistance at $3.50.
The stock has traded within a 30-day range of $2.34 to $5.23, reflecting notable near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $3.31 | $5.58 | 0% | Neutral | |
| $3.93 | $5.46 | $8.21 | +65% | Bullish | |
| $5.08 | $7.49 | $11.97 | +126% | Bullish | |
| $5.20 | $8.06 | $13.52 | +144% | Bullish | |
| $4.49 | $7.31 | $12.74 | +121% | Bullish | |
| $4.85 | $8.24 | $14.87 | +149% | Bullish | |
| $5.04 | $8.93 | $16.59 | +170% | Bullish | |
| $6.04 | $11.15 | $21.30 | +237% | Bullish | |
| $7.67 | $14.73 | $28.83 | +345% | Bullish | |
| $8.09 | $16.14 | $32.32 | +388% | Bullish | |
| $11.00 | $24.44 | $53.77 | +638% | Bullish | |
| $19.68 | $43.73 | $100.57 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.12 | $3.31 | $3.96 | +0.00% |
| June 2026 | $2.78 | $3.33 | $4.14 | +0.57% |
| July 2026 | $2.71 | $3.30 | $4.21 | -0.84% |
| August 2026 | $2.93 | $3.63 | $4.71 | +9.84% |
| September 2026 | $3.01 | $3.77 | $4.97 | +3.91% |
| October 2026 | $2.82 | $3.56 | $4.77 | -5.39% |
| November 2026 | $2.87 | $3.66 | $4.96 | +2.74% |
| December 2026 | $3.17 | $4.07 | $5.58 | +11.16% |
Click any year to see its month-by-month LTRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LTRN to range from $1.12 to $5.58 through 2026. The $3.31 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The LTRN price prediction for 2027 points to an average of $5.46 (low $3.93, high $8.21) — a potential gain of +65% on today's $3.31. Momentum favours further upside here.
In 2028, LTRN is projected to trade between $5.08 and $11.97, averaging $7.49 — a potential gain of +126% from today's $3.31. That is up +37% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Lantern Pharma Inc.'s 2029 outlook centres on $8.06, within a $5.20 to $13.52 range. That is up +8% on the projected 2028 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2030, LTRN could reach as high as $12.74, with a base case around $7.31 and support toward $4.49 — roughly +121% from $3.31. Buyers look set to stay in control over this stretch.
Expect LTRN to range from $4.85 to $14.87 through 2031. The $8.24 average target implies a +149% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The LTRN price prediction for 2032 points to an average of $8.93 (low $5.04, high $16.59) — a potential gain of +170% on today's $3.31. Buyers look set to stay in control over this stretch.
In 2033, LTRN is projected to trade between $6.04 and $21.30, averaging $11.15 — a potential gain of +237% from today's $3.31. That is up +25% on the projected 2032 average. Momentum favours further upside here.
Lantern Pharma Inc.'s 2034 outlook centres on $14.73, within a $7.67 to $28.83 range. That is up +32% on the projected 2033 average. That marks a +345% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, LTRN could reach as high as $32.32, with a base case around $16.14 and support toward $8.09 — roughly +388% from $3.31. Momentum favours further upside here.
Expect LTRN to range from $11.00 to $53.77 through 2040. The $24.44 average target implies a +638% move from current prices. That is up +51% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The LTRN price prediction for 2050 points to an average of $43.73 (low $19.68, high $100.57) — a potential gain of +12.2x on today's $3.31. Momentum favours further upside here.
Investing $1,000 in LTRN today (≈ 302.114804 LTRN) could be worth
$13,210.33
+$12,210.33 (+1221%) by 2050 · US Dollar
Based on the average projected LTRN price of $43.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LTRNwould be worth at today's price.
$1,000 invested in LTRN on May 27, 2025 (≈ 344.827575 LTRN) would be worth
$1,141.38
+$141.38 (+14.1%) today · 1.14× · US Dollar
Based on a LTRN entry price of $2.9 vs. today's $3.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.17 | $1,044.16 | +4.4% |
| 1 month ago | $2.46 | $1,345.53 | +34.6% |
| 3 months ago | $2.84 | $1,165.49 | +16.5% |
| 6 months ago | $3.62 | $914.36 | -8.6% |
| 1 year ago | $2.9 | $1,141.38 | +14.1% |
| All time (5.0y) ago | $14.39 | $230.02 | -77.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LTRN forecast.
Our base-case forecast reaches $6.60 around 2028.
Implied market cap at $6.60: $84.21M
The multi-year forecast shows a strong long-run upside, with the 2026 average price at $3.50 and a max of $6.23, though the 2026 forecast is noted as Neutral. From 2027 onward, the outlook becomes bullish with higher average prices and rising ROIs: 2027 average $6.24, max $9.39, ROI 78.3; 2028 average $8.66, max $13.86, ROI 147.5; 2029 average $9.48, max $15.90, ROI 170.9; 2030 average $8.65, max $15.08, ROI 147. The forecast continues to glow with 2031 average $10.29, max $18.56, ROI 193.9; 2032 average $11.52, max $21.43, ROI 229.3; 2033 average $14.74, max $28.16, ROI 321; 2034 average $19.77, max $38.73, ROI 465; 2035 average $21.54, max $43.16, ROI 515.5.
The longer horizon shows substantial upside, with 2040 average $35.73, max $78.60, ROI 920.8, and 2050 average $64.64, max $148.67, ROI 1746.8. Overall the years beyond 2026 carry a bullish sentiment and substantial upside potential, recognizing that these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.65, a minimum of $5.31, and a maximum of $15.08, with a projected ROI of 147 and a bullish sentiment.
Forecasts indicate a Neutral stance in 2026, followed by a Bullish sentiment from 2027 onward, with rising average prices and higher maxima through 2050. These are estimates and not guarantees.
Yes. The 2030 forecast lists a maximum of $15.08, with an average of $8.65 and a minimum of $5.31.
Current price is $3.50 and market cap is $44.66M.
Annualized volatility is 100%.
Lantern Pharma Inc. Community Discussion
0Share your Lantern Pharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.